Alex Badamchi-Zadeh

Alex is a Senior Associate in the Biotech Investment team at SV, where he forms and fund transatlantic companies developing transformational new medicines. Alex serves as a board observer at Alchemab Therapeutics, EyeBio and TRexBio - three SV created companies, and is on the investment committee of the Cancer Research Horizons Seed Fund.

Prior to joining SV, Alex led Business Development and Strategy for the Immuno-oncology focused biotech Xilio Therapeutics (NASDAQ: XLO), including through its $100.5m Series B equity raise. Alex was a Life Science Specialist Consultant at L.E.K. Consulting in Boston MA, where he advised investors and executives in the life sciences industry (biotech, pharmaceuticals, diagnostics, and medical devices) on corporate, business unit, franchise and product strategic decisions. Alex was a Postdoctoral Fellow in Dr Dan Barouch’s lab at Harvard Medical School developing the Ad26 vaccine platform for infectious disease and cancer. He has authored over a dozen scientific publications (Nature, Science Immunology, Journal of Immunology), and was part of the team to develop the world’s first Zika virus vaccine in response to the 2016 epidemic. Alex received his MRes and PhD in Medicine (Immunology) from Imperial College London, and holds a BA (Hons) in Biological Sciences from Christ Church, University of Oxford.